A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
09/2011
09/29/2011	WO2011118976A2 Pharmaceutical composition for the prevention or the treatment of non-alcoholic fatty liver disease and the method for prevention or treatment of non-alcoholic fatty liver disease using the same
09/29/2011	WO2011118891A1 Pharmaceutical composition including sulfuretin or pharmaceutically acceptable salt thereof for prevention and treatment of nervous system disorder
09/29/2011	WO2011118843A1 Glutamate derivatives or salts thereof
09/29/2011	WO2011118818A1 Amidinoaneline derivative
09/29/2011	WO2011118812A1 Neurodegenerative disease therapeutic agent
09/29/2011	WO2011118810A1 Nutritional composition
09/29/2011	WO2011118779A1 Pharmaceutical composition for treatment and prevention of herpesvirus infections
09/29/2011	WO2011118778A1 Cell proliferation suppression agent and method for screening same
09/29/2011	WO2011118759A1 Benzanilide derivative
09/29/2011	WO2011118683A1 Patch for medical use
09/29/2011	WO2011118682A1 Aptamer for ngf and use thereof
09/29/2011	WO2011118672A1 Plasma kallikrein inhibitor
09/29/2011	WO2011118604A1 Hydrous adhesive patch
09/29/2011	WO2011118552A1 Anti-allergic agent
09/29/2011	WO2011118481A1 Method for reducing unpleasant taste
09/29/2011	WO2011118468A1 Wake-time-extending agent
09/29/2011	WO2011118088A1 Feed containing γ-aminobutyric acid, process for production of same, and method for farming of livestock animals using same
09/29/2011	WO2011117894A1 Pharmaceutical technology of pharmaceutical composition in novel/sequential drug delivery system containing nitric oxide donor
09/29/2011	WO2011117884A1 Stable pharmaceutical compositions comprising fesoterodine
09/29/2011	WO2011117883A1 Pharmaceutical composition of mycophenolate mofetil and process for preparing thereof
09/29/2011	WO2011117882A1 Pyrrolo[2,l-c][l,4]benzodiazepine-benzothiazole or benzoxazole conjugates linked through piperazine moiety and process for the preparation thereof
09/29/2011	WO2011117875A1 Salts of fluvastatin and process for the preparation of substantially amorphous fluvastatin sodium
09/29/2011	WO2011117870A2 Compositions for topical administration
09/29/2011	WO2011117830A1 Derivatives of phenazine useful to treat cancer
09/29/2011	WO2011117798A1 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
09/29/2011	WO2011117749A1 Compound and method for the treatment of pain
09/29/2011	WO2011117711A1 Pharmaceutical composition comprising a pyrimidineone derivative
09/29/2011	WO2011117690A1 Hydroxy-2,3-diarylxanthones as therapeutic agents of pathologies due to reactive oxygen species
09/29/2011	WO2011117668A1 Carbazole linked pyrrolo[2,1-c][1,4]benzodiazepine hybrids as potential anticancer agents and process for the preparation thereof
09/29/2011	WO2011117568A1 Compounds targeting the vegf and/or hif pathway such as sorafenib or vatalanib for use in the treatment of otitis media
09/29/2011	WO2011117453A1 Use of compounds with a 2-cyclopentenone structure for the inhibition of enzymes of the family of aldo-keto reductases
09/29/2011	WO2011117449A1 Enantiomers of benzoheteroepine derivatives and use thereof as anti-carcinogenic agents
09/29/2011	WO2011117429A1 Cannabinoid quinone derivatives
09/29/2011	WO2011117424A1 Viral inhibitor compositions for in vivo therapeutic use comprising a combination of (-) -carvone, geraniol and a further essential oil component
09/29/2011	WO2011117391A2 Novel composition for treatment of essential thrombocythemia
09/29/2011	WO2011117382A1 Pyridyltriazoles
09/29/2011	WO2011117381A1 B-raf kinase inhibitors
09/29/2011	WO2011117378A2 Improved methods and compositions for safe and effective treatment of telangiectasia
09/29/2011	WO2011117377A2 Improved methods and compositions for safe and effective treatment of erythema
09/29/2011	WO2011117362A1 Use of iminocyclitols as inhibitors of bacterial adherence to epithelial cells
09/29/2011	WO2011117353A1 Bivalent antisense oligonucleotides
09/29/2011	WO2011117346A1 Endoparasiticidal compositions
09/29/2011	WO2011117322A2 Use of caffeine and aspirin in synergistic amounts for improving performance
09/29/2011	WO2011117313A1 Fast dissolving drug delivery systems
09/29/2011	WO2011117306A1 Double-layer pharmaceutical formulations containing opioid agonists and antagonists
09/29/2011	WO2011117305A1 Azo compounds reducing formation and toxicity of amyloid beta aggregation intermediates
09/29/2011	WO2011117295A1 1-[(3-cyano-pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(r)-amin0-piperidin-1-yl]-xanthine for the treatment of a metabolic disorder of a predominantly carnivorous non-human animal
09/29/2011	WO2011117289A1 Chromen-2-one derivatives and their use as monoamine neuro-transmitter re-uptake inhibitors
09/29/2011	WO2011117264A1 N-(imidazopyrimidin-7-yl)-heteroarylamide derivatives and their use as pde10a inhibitors
09/29/2011	WO2011117254A1 Piperidine amides as modulators of the ghrelin receptor
09/29/2011	WO2011117225A1 Fe(iii) complex compounds for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anemias
09/29/2011	WO2011117163A1 Cyclopentyl - and cycloheptylpyrazoles as fxr modulators
09/29/2011	WO2011117160A1 Pyrrolopyrazine derivatives and their use as jak and syk inhibitors
09/29/2011	WO2011117145A2 Pyrrolopyrazine kinase inhibitors
09/29/2011	WO2011116973A1 Method of preparing a granulated pharmaceutical composition comprising simvastatin and/or ezetimibe
09/29/2011	WO2011116951A1 Pharmaceutically active disubstituted triazine derivatives
09/29/2011	WO2011116909A1 Pharmaceutical compositions containing substituted 6-deoxy-6-sulfanylcyclodextrin
09/29/2011	WO2011116867A1 Benzonaphthyridinamines as autotaxin inhibitors
09/29/2011	WO2011116663A1 2',2-dithiazol non-nucleoside compounds, preparation methods, pharmaceutical compositions and uses as hepatitis virus inhibitors thereof
09/29/2011	WO2011097148A3 Use of oral heparin preparations to treat urinary tract diseases and conditions
09/29/2011	WO2011095764A3 Antimicrobial compounds
09/29/2011	WO2011093742A3 Agent for treating parkinson's disease
09/29/2011	WO2011092708A3 Liposomes comprising amphipathic drugs and method for their preparation
09/29/2011	WO2011090760A4 Heteroaryl compounds and uses thereof
09/29/2011	WO2011087712A3 Tricyclic derivatives and their pharmaceutical use and compositions
09/29/2011	WO2011086531A3 New anti-malarial agents
09/29/2011	WO2011086507A8 "compositions comprising amino acids for prevention and/or treatment of renal disorders"
09/29/2011	WO2011085979A4 Use of tricyclic sesquiterpene lactones in the treatment of obesity and related diseases and non-therapeutic treatable conditions
09/29/2011	WO2011080132A3 Compounds, compositions and methods for controlling biofilms
09/29/2011	WO2011073981A3 Betahistine in compositions and methods for treating somnolence
09/29/2011	WO2011064354A3 Micro-rna and tissue repair
09/29/2011	WO2011062766A3 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties
09/29/2011	WO2011061744A3 Novel arylated camphenes, processes for their preparation and uses thereof
09/29/2011	WO2011061498A3 Inhalation solutions
09/29/2011	WO2011060213A3 Preparation of sitagliptin and salts thereof
09/29/2011	WO2011059821A3 Cyclohexane-1,3-diones for use in the treatment of amyotrophic lateral sclerosis
09/29/2011	WO2011059733A3 Use of lipoic acid in cell transplantation
09/29/2011	WO2011056957A3 Enzyme inhibiting compounds
09/29/2011	WO2011056793A3 Composition, method, and kit for alpha-1 proteinase inhibitor
09/29/2011	WO2011056604A3 Treatment of sunburn using analgesics and antihistamines
09/29/2011	WO2011056486A3 Devices, methods, and composition for controlling infections
09/29/2011	WO2011053801A3 Methods and cosmetic preparations for the sustained delivery of therapeutic agents to the eye
09/29/2011	WO2011050319A3 Inhibiting the deleterious effect of anthracyclines
09/29/2011	WO2011046381A3 COMPOSITION FOR INHIBITING TGF-β COMPRISING IMIDAZOPURINE DERIVATIVES
09/29/2011	WO2011044511A3 Rage regulates rock activity in cardiovascular disease
09/29/2011	WO2011043568A3 Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same
09/29/2011	WO2011041512A3 Compositions and methods for treating mlv-infection, and preventing and treating mlv-initiated diseases
09/29/2011	WO2011035343A3 Phentermine liquid dosage form
09/29/2011	WO2011026125A3 Gastric retentive pharmaceutical compositions for immediate and extended release of acetaminophen
09/29/2011	WO2011009890A3 Use of azabicycloalkyl derivatives or pyrrolidine - 2 - one derivatives for the treatment or prevention of ataxia
09/29/2011	WO2010151815A3 3,9-diazaspiro[5,5]undecane amides and ureas and methods of use thereof
09/29/2011	WO2010149760A3 Mexiletine amino acid and peptide prodrugs and uses thereof
09/29/2011	WO2010138539A3 Reduction of flake-like aggregation in nanoparticulate active agent compositions
09/29/2011	WO2010127152A3 Compounds and compositions as microsomal prostaglandin e synthase-1 inhibitors
09/29/2011	WO2010126370A3 Means and methods for counteracting, preventing and/or determining heart failure, or a risk of heart failure
09/29/2011	WO2010119364A3 A medicinal cream made using neomycin sulphate, betamethasone valerate, and chitosan, and a process to make the same
09/29/2011	WO2009123486A8 Use of compounds in the treatment of tau-induced cytotoxicities
09/29/2011	US20110239312 Methods of diagnosing and treating motor neuron diseases
09/29/2011	US20110238036 Sustained release delivery devices
09/29/2011	US20110238016 Drug delivery to a joint

1 ... 1542 1543 1544 1545 1546 1547 1548 1549 1550 1551 1552 1553 1554 1555 1556 1557 1558 1559 1560 1561 1562 ... 7860